Long-Term Liabilities: The sum of all non-current liabilities.
Keros Therapeutics, Inc. (KROS) had Long-Term Liabilities of $14.47M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$244.06M |
|
$87.01M |
|
-- |
|
$244.06M |
|
$176.49M |
|
$67.57M |
|
$24.33M |
|
$91.90M |
|
$91.90M |
|
$87.01M |
|
$87.01M |
|
$87.01M |
|
$87.01M |
|
$67.57M |
|
$69.08M |
|
37.22M |
|
37.86M |
|
$2.34 |
|
$2.30 |
|
| Balance Sheet Financials | |
$315.43M |
|
$4.30M |
|
$22.59M |
|
$338.02M |
|
$20.41M |
|
-- |
|
|
Long-Term Liabilities |
$14.47M |
$34.89M |
|
$303.13M |
|
$303.13M |
|
$303.13M |
|
19.54M |
|
| Cash Flow Statement Financials | |
$107.50M |
|
$-1.55M |
|
$-378.47M |
|
$561.38M |
|
$288.86M |
|
$-272.52M |
|
$28.70M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
27.69% |
|
27.69% |
|
28.30% |
|
37.65% |
|
35.65% |
|
$105.95M |
|
-- |
|
-- |
|
-- |
|
0.72 |
|
-- |
|
41.96 |
|
8.70 |
|
28.70% |
|
28.70% |
|
25.74% |
|
28.70% |
|
$15.51 |
|
$2.80 |
|
$2.84 |
|